Uncovering the genetic architecture of ME/CFS: a precision approach reveals impact of rare monogenic variation.
Birch, Camille L, Wilk, Brandon M, Gajapathy, Manavalan et al. · Journal of translational medicine · 2025 · DOI
Quick Summary
Researchers studied the DNA of 31 people with ME/CFS from 25 families to find genetic causes of the illness. They found that about 39% of participants had gene mutations that could contribute to ME/CFS, and these mutations affected how bodies produce energy and handle stress. While the specific genes varied between patients, they all seemed to affect similar biological pathways, suggesting ME/CFS may be caused by different genetic problems that lead to the same symptoms.
Why It Matters
This study provides evidence that at least some ME/CFS cases have identifiable genetic causes affecting energy metabolism and stress response, potentially opening doors to targeted treatments and biomarkers. By demonstrating convergence of diverse genetic variants onto shared biological pathways, it suggests that precision medicine approaches tailored to individual genetic profiles could improve diagnosis, trial design, and therapeutic development for this historically neglected condition.
Observed Findings
Pathogenic or likely pathogenic variants were identified in 39% of affected individuals (12/31) and 32% of probands (8/25).
Genetic variants implicated pathways including ATP generation, oxidative phosphorylation, fatty acid oxidation, glycolysis regulation, ion homeostasis, synaptic signaling, and muscle integrity.
Despite genetic diversity at the gene level, downstream effects converged on impaired energy production, reduced stress resilience, and vulnerability to post-exertional metabolic failure.
RNA-seq analysis was performed in 16 affected and 7 unaffected individuals to identify transcriptomic signatures.
GeneticModifiers were identified that may influence disease onset, severity, and relapsing-remitting patterns, potentially explaining intrafamilial variability.
Inferred Conclusions
At least a subset of ME/CFS cases represents distinct molecular disorders that converge on shared physiological pathways affecting energy metabolism and stress resilience.
An individualized precision medicine framework integrating genomic data with deep phenotyping can identify molecular drivers previously obscured by heterogeneity.
Future progress in ME/CFS research requires experimental designs beyond increasing sample size alone, incorporating both rare and common variants and environmental modifiers.
Remaining Questions
What is the generalizability of these findings to larger, more diverse ME/CFS populations, and how many patients carry similar pathogenic variants?
What This Study Does Not Prove
This study does not establish that genetics causes all ME/CFS cases—only that genetic factors may contribute to a subset of patients. The findings are not yet validated in larger, more diverse populations, so the prevalence and relevance of identified variants remain uncertain. The study also cannot determine whether identified variants are sufficient to cause disease or require environmental triggers and other modifiers.